Bexlutry (lutetium lu-177 dotatate)

Where it stands

Bexlutry (lutetium Lu-177 dotatate), from Curium, was approved by the US FDA on 2026-09-14 under NDA218525. The records list this as an official FDA approval milestone. The dosage form is given as a solution.

The records leave several fields blank: therapeutic area, indication and CHMP opinion date. This analysis therefore cannot say which patient population or disease setting the label covers, and it makes no assumptions about them. The record shows no European (CHMP) opinion, so there is nothing on EU status.

Regulatory pathway and designations

The only designation recorded is "New formulation or manufacturer". The FDA milestone text repeats this classification. In general terms, this signals that the approval concerns a new presentation or a new sponsor or manufacturing source of an active ingredient. It does not imply a new molecular entity. The records do not say which NDA subtype or pathway was used, and they do not name a reference product. Any assumption about reliance on prior data would go beyond the records.

No expedited-program designations (such as priority review, fast track or orphan status) appear in the records. Nor do they list a PDUFA goal date, advisory committee activity or any post-approval commitments.

Safety and pharmacovigilance

The records contain no safety data, such as warnings, adverse event rates, REMS requirements or postmarketing requirements. This analysis therefore makes no product-specific safety statements.

Professionals should read the FDA-approved prescribing information for NDA218525 for the boxed warnings (if any), contraindications, dosing and radiation-handling instructions. They should also check how the Bexlutry label compares with other products containing the same active substance.

What to watch

The first step is to retrieve the approved label and the FDA review documents. These should confirm the indication, the basis of approval, the formulation differences and any postmarketing commitments. The records do not currently supply any of these.

Other items to track are whether Curium files in the EU or other regions, and any launch, supply or manufacturing announcements. None of these appear in the records, so no timing or outcome can be stated.